ICCM On Other Exchanges
Tel Aviv

icecure medical ltd (ICCM) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ICECURE MEDICAL LTD (ICCM)

Related News

No related news articles were found.

icecure medical ltd (ICCM) Related Businessweek News

No Related Businessweek News Found

icecure medical ltd (ICCM) Details

IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women’s health and oncology markets. The company offers IceSense3, a cryoablation system for breast tumors. IceCure Medical Ltd was founded in 2006 and is based in Caesarea, Israel.

Founded in 2006

icecure medical ltd (ICCM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

icecure medical ltd
IceCure Medical Announces New Category III CPT Code for Breast Cryoablation Therapy, Issued by the American Medical Association

IceCure Medical Ltd. announced that its application for a new CPT code, describing the use of cryoablation for treating cancerous breast tumors, has been approved by the American Medical Association (AMA). Category III CPT Codes are typically issued for emerging innovative technologies and procedures, to support better tracking in the use of these procedures. These codes also enable providers to apply for reimbursement for procedures using cryoablation therapy for ablating malignant breast tumors. Category III CPT Codes are generally limited to a number of years, until the requirements for a Category I CPT code are met. IceCure expects that the new reimbursement code will provide important support for further adoption of cryoablation therapy for breast cancer. The growing recognition of the role of cryoablation in managing breast cancer is further evidenced by the presentation, in May 2018, of the interim results from the landmark ICE3 clinical study. ICE3 is the controlled multicenter clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them. The company is currently in discussions with the Food and Drug Administration (FDA) to expand the use of its cryoablation system, ProSense™, to enable minimally-invasive cryoablation treatment of cancerous breast tumors. ProSense™ is already cleared by the FDA for use as a non-surgical solution to treat non-cancerous breast tumors (Fibroadenoma) in outpatient and office settings.

IceCure Medical Ltd, Special/Extraordinary Shareholders Meeting, Jul 02, 2019

IceCure Medical Ltd, Special/Extraordinary Shareholders Meeting, Jul 02, 2019, at 12:00 Israel Standard Time.

IceCure Medical Ltd Auditor Raises 'Going Concern' Doubt

IceCure Medical Ltd filed its Annual on Mar 28, 2019 for the period ending Dec 31, 2018. In this report its auditor, Brightman Almagor Zohar & Co, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ICCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICCM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ICCM Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ICECURE MEDICAL LTD, please visit www.icecure-medical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.